➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
Mallinckrodt
Colorcon
Johnson and Johnson

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAZVERIK

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Tazverik

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04537715 ↗ A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat Recruiting Epizyme, Inc. Phase 1 2020-04-23 This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
NCT04557956 ↗ Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment Not yet recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2020-12-04 This phase I/II trial investigates the best dose and side effects of tazemetostat and how well it works in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat with dabrafenib and trametinib may help treat patients with BRAFV600 mutated melanoma.
NCT04624113 ↗ Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Not yet recruiting Epizyme, Inc. Phase 1/Phase 2 2021-01-31 The primary aim of the phase 1 portion of the trial is to establish the recommended phase 2 dose (RP2D) of tazemetostat in combination with a fixed dose of pembrolizumab in patients with recurrent or metastatic (RM) head and neck cancer. The primary aim of the phase 2 portion of the trial is to establish the proportion of patients with pembrolizumab- or nivolumab-resistant, PD-L1 positive, RM head and neck squamous-cell carcinoma (HNSCC) who achieve an objective tumor response to tazemetostat and pembrolizumab.
NCT04624113 ↗ Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Not yet recruiting Washington University School of Medicine Phase 1/Phase 2 2021-01-31 The primary aim of the phase 1 portion of the trial is to establish the recommended phase 2 dose (RP2D) of tazemetostat in combination with a fixed dose of pembrolizumab in patients with recurrent or metastatic (RM) head and neck cancer. The primary aim of the phase 2 portion of the trial is to establish the proportion of patients with pembrolizumab- or nivolumab-resistant, PD-L1 positive, RM head and neck squamous-cell carcinoma (HNSCC) who achieve an objective tumor response to tazemetostat and pembrolizumab.
NCT04846478 ↗ Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Not yet recruiting Epizyme, Inc. Phase 1 2021-07-01 This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: - Talazoparib - Tazemetostat
NCT04846478 ↗ Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Not yet recruiting Pfizer Phase 1 2021-07-01 This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: - Talazoparib - Tazemetostat
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tazverik

Condition Name

Condition Name for Tazverik
Intervention Trials
Solid Tumor 2
Clinical Stage IV Cutaneous Melanoma AJCC v8 1
Mesothelioma 1
Pathologic Stage IV Cutaneous Melanoma AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tazverik
Intervention Trials
Neoplasms 3
Melanoma 1
Nerve Sheath Neoplasms 1
Lymphoma, Large B-Cell, Diffuse 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tazverik

Trials by Country

Trials by Country for Tazverik
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tazverik
Location Trials
South Carolina 1
Florida 1
Massachusetts 1
Missouri 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tazverik

Clinical Trial Phase

Clinical Trial Phase for Tazverik
Clinical Trial Phase Trials
Phase 2 2
Phase 1/Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tazverik
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tazverik

Sponsor Name

Sponsor Name for Tazverik
Sponsor Trials
Epizyme, Inc. 5
Pfizer 1
Washington University School of Medicine 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tazverik
Sponsor Trials
Industry 6
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Express Scripts
McKesson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.